More than 40% of patients receiving antibody-drug conjugates (ADCs) will experience ocular toxicities during treatment, ONS members Caroline Clark, MSN, APRN, OCN^®, AGCNS, EBP-C, and Ikuko Komo, MSN, CNS, NP, AOCNS^®, AOCNP^®, reported in an article in the April 2024 issue of the Clinical Journal of Oncology Nursing.

On April 29, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv (Tivdak^®) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for the indication.